28 February 2018

Smith+Nephew to sponsor Hulls Freedom Festival Arts Trust

Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, is pleased to announce its sponsorship of Freedom Festival Arts Trust. The Hull (UK) based Freedom Festival celebrates the city’s independent spirit and historic contribution to the cause of freedom through artistic and cultural expression.

The Freedom Festival is the lasting legacy of the Wilberforce 2007 campaign, which celebrated the bicentenary of the abolition of the slave trade, led by Hull-born MP William Wilberforce in 1807.

 “As a Company with its roots deeply embedded in this city we are excited to continue contributing to a positive change in the region” said Sue Myers, Senior Director, Communication, Smith & Nephew. “Smith & Nephew is proud to continue giving employees the opportunity to be part of Hull’s cultural fabric by supporting Freedom Festival, which follows our successful sponsorship of Hull’s City of Culture celebrations in 2017.”

Last year’s Freedom Festival saw an estimated audience of 150,000 people enjoy more than 200 acts from across the world performing in Hull’s streets and spaces. While the festival itself is for one weekend in the year, Smith & Nephew will enjoy a year round association with the Freedom Festival Arts Trust which aims to nurture and support local and regional creative talent while also continuing to attract national and international artists and collaborators.

Jenny Howard-Coombes, Executive Director at Freedom Festival Arts Trust, said: “Freedom Festival would not be possible without our partners, sponsors and friends of Freedom. We are delighted to welcome Hull-based Smith & Nephew into our Freedom Family. Hull’s creativity and passion has been ignited over recent years and we are keen to build on the interest in arts and culture for all to enjoy having seen first-hand the impact it can have on a city and its people.

“Just like Smith & Nephew, we are firmly rooted in the city and we’re looking forward to another incredible year.”

Founded in Hull over 160 years ago by Thomas James Smith, the Company has grown from a Whitefriargate pharmacy to a global supplier of advanced medical devices with more than 15,000 employees. During the First World War, the firm specialised in the supply of field dressings, and now manufactures pioneering products used by healthcare professionals in more than 100 countries.



Sue Myers
+44 (0) 1482 673229
Smith & Nephew plc

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to supporting healthcare professionals in their daily efforts to improve the lives of their patients. With leadership positions in Orthopaedic ReconstructionAdvanced Wound ManagementSports Medicine and Trauma & Extremities, Smith & Nephew has more than 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were almost $4.8 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).

For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.comfollow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com


Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

◊ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.